Alnylam Pharmaceuticals (ALNY) Expected to Release Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.63 per share and revenue of $1.3221 billion for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue was up 96.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.44) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $7 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Up 3.6%

ALNY stock opened at $288.41 on Wednesday. Alnylam Pharmaceuticals has a one year low of $262.21 and a one year high of $495.55. The firm has a market cap of $38.51 billion, a PE ratio of 78.80 and a beta of 0.27. The firm’s 50 day moving average price is $291.94 and its 200-day moving average price is $314.22. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent analyst reports. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. decreased their price target on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. Bank of America lowered their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Friday, July 10th. Finally, HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $452.13.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Golden State Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $39,000. Finally, Colonial Trust Co SC increased its position in shares of Alnylam Pharmaceuticals by 160.5% during the fourth quarter. Colonial Trust Co SC now owns 99 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 61 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.